September 2020 • PharmaTimes Magazine • 4-5

Contents

Features

Oli Hudson considers how pharma should align its brand strategy with the NHS reset during the COVID recovery era

Jo Spadaccino's take on how the NHS is tackling the third phase of its COVID-19 response, and the potential implication for pharma

James Osborn says there's a real opportunity to help tackle health inequality across populations by keeping health literacy front of mind

Janssen's Joaquín Casariego says pharma can do more to ensure patients are truly front and centre

Analysis

What can the world learn from the UK pharma's industry? Jameel Zayed looks at how the UK model could provide other countries with valuable insight for generating outcomes and growth

What does pharma have left to fight for? The industry needs to move on from the EU trade deal, says Paul McGrade

Janssen's Joaquín Casariego says pharma can do more to ensure patients are truly front and centre

Monia Nica outlines the temporary changes to EU regulatory requirements spurred by the coronavirus pandemic

SmartPeople

Harmony talks to PharmaTimes about her role as ViiV Healthcare’s chief medical officer and head of Global Medical

We talk to Janssen’s Neil Davie about his role at the firm and the current challenges for patients with pulmonary hypertension

Ellie shares her experiences with the rare disorder cutaneous T-cell lymphoma (CTCL)

Business Insight

How Rosemont Pharma has  been moving with the times for more has 50 years